Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price traded up 4.2% on Tuesday. The stock traded as high as $78.0250 and last traded at $77.66. Approximately 1,222,038 shares were traded during trading, an increase of 546% from the average daily volume of 189,291 shares. The stock had previously closed at $74.51.
Gemini Therapeutics Trading Up 4.1%
The business’s 50-day moving average is $71.21 and its two-hundred day moving average is $70.72. The stock has a market capitalization of $3.60 billion, a PE ratio of -83.20 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc was a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases, with an initial emphasis on ophthalmic conditions. The company sought to use insights from human genetics to identify therapeutic targets and develop treatments for patients with serious retinal disorders.
Gemini’s lead program was GEM103, a recombinant form of complement factor H designed to address dysregulation of the complement system. The program was investigated as a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration, and other diseases associated with complement-factor-H biology.
Gemini Therapeutics combined with Disc Medicine in 2021.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
